Indications |
Oral Allergic conditions, Pruritic skin disorders Adult: Up to 6 mg daily in 3-4 divided doses. |
Contraindications |
Severe liver disease; avoid alcohol; premature infants or full-term neonates. |
Warnings / Precautions |
May impair ability to drive and operate machinery. Angle-closure glaucoma, urinary retention, prostatic hypertrophy or pyloroduodenal obstruction; epilepsy; hepatic impairment. Elderly. Pregnancy and lactation. |
Adverse Reactions |
Sedation; antimuscarinic effects, CNS depression and disturbances; occasionally, paradoxical CNS stimulation esp in child; psychomotor impairment; headache; palpitations and arrhythmias. Convulsions, sweating, myalgia, paraesthesias, extrapyramidal symptoms, tremor, sleep and GI disturbances, hypersensitivity reactions and blood disorders; tinnitus, hypotension; hair loss. |
Drug Interactions |
Enhance effects of CNS depressants eg, alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives and antipsychotics. Atropine, tricyclic antidepressants (TCAs), MAOIs. Can mask signs of ototoxicity caused by aminoglycosides. May antagonise the action of betahistine. Increased risk of seizure when used with bupropion. Concurrent use with mefloquine may lead to prolongation of the QT interval. See Below for More diphenylpyraline hydrochloride Drug Interactions |
Lab Interactions |
May interfere with skin testing. |
Mechanism of Actions |
Diphenylpyraline, a piperidine derivative, is an antihistamine with antimuscarinic and significant sedative properties. |
ATC Classification |
R06AA07 - diphenylpyraline ; Belongs to the class of aminoalkyl ethers used as systemic antihistamines. |
Available As |
|
Diphenylpraline
Post Review about Diphenylpraline Click here to cancel reply.
Diphenylpraline Containing Brands
Diphenylpraline is used in following diseases
Drug - Drug Interactions of Diphenylpraline
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.